TB-500 in the UK: MHRA regulatory status

TB-500 has no marketing authorisation in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a product licence for any TB-500 or thymosin beta-4 formulation, and none is pending.^[1] That single fact determines almost everything downstream: how the product is classified at the border, whether a pharmacist can dispense it, and what a UK athlete risks by using it. This article works through each of those questions from the primary regulatory sources.

What the MHRA classification means

The Human Medicines Regulations 2012 define a medicinal product as any substance that is presented as having properties for treating or preventing disease in humans, or that can be administered to humans with a view to restoring, correcting, or modifying physiological functions.^[2] TB-500 is sold online with claims about tissue repair, tendon healing, and cardiac recovery. Those claims are enough to bring it inside the medicines definition regardless of how the seller labels the packaging.

Under Regulation 46 of those same regulations, no person may sell or supply, or offer to sell or supply, an unauthorised medicinal product.^[3] A product is authorised when it holds one of four instruments: a UK marketing authorisation, a certificate of registration, a traditional herbal registration, or an Article 126a authorisation. TB-500 holds none of these. It is therefore an unauthorised medicinal product under UK law.

The MHRA's product register confirms no licensed product contains thymosin beta-4 or the heptapeptide fragment AC-LKKTETQ (the molecule sometimes sold as TB-500). The European Medicines Agency reached the same conclusion for the EU market: no marketing authorisation, EPAR, or referral exists for thymosin beta-4 in any formulation.

The only legal supply route: the 'specials' framework

UK law does allow unlicensed medicines to be supplied in one narrow circumstance. Regulation 167 of the Human Medicines Regulations 2012 permits a licensed prescriber to request an unlicensed 'special' product for a specific named patient, provided the product is manufactured or imported against that prescriber's written request.^[4] The prescriber takes on clinical responsibility for the decision.

This is not a route that a private individual can use by ordering directly from an overseas vendor. The specials pathway requires a licensed UK prescriber on record and, on the supply side, either a Manufacturer's Specials Licence or a Wholesale Dealer's Licence granted by the MHRA, depending on whether the product originates inside or outside the country. A grey-market vendor shipping vials from the US or China holds neither.

In practice, most UK prescribers would decline to request TB-500 as a special. There are no completed Western-standard randomised controlled trials of systemic TB-500 or thymosin beta-4 for the musculoskeletal and tissue-repair indications that drive grey-market demand. The only Phase 3 human safety data sits in ophthalmology, covering a topical eye-drop formulation. A prescriber accepting clinical responsibility for a subcutaneous injection product with no human trial data in that indication is taking on significant liability, and the GMC's prescribing standards require a clear justification.

Importing TB-500 into the UK

Any business importing an unlicensed medicine from outside the UK must notify the MHRA before import and may only proceed if the MHRA does not object.^[5] Importers from non-approved countries require a Manufacturer's Specials Licence; importers from approved countries require a Wholesale Dealer's Licence. A Qualified Person must certify each batch. None of this applies to a private individual ordering a vial through a website.

For private individuals, the UK government's guidance allows a traveller to bring up to three months' supply of a medicine they hold a valid prescription for.^[6] TB-500 is not licensed anywhere in the world, so there is no valid prescription to show. Customs can treat parcels of TB-500 arriving by post as unlicensed medicines and seize them. The 'research use only' label that many vendors print on the vial does not change the MHRA's analysis: what matters is whether the substance meets the medicines definition, not what the outer packaging says.

Seizure of a shipment does not automatically lead to criminal prosecution, but it does mean the product is lost. MHRA enforcement teams have powers under Part 16 of the Human Medicines Regulations to inspect, sample, and seize unlicensed medicines at the border and at sorting offices. Enforcement attention tends to focus on sellers operating from UK addresses, but the legal exposure for buyers is real and the practical risk of seizure depends on volume, frequency, and how the parcel is declared, not on whether the activity is lawful.

TB-500 and UK anti-doping rules

For athletes, there is a separate layer. The World Anti-Doping Agency (WADA) added thymosin beta-4 and its derivatives, including TB-500, to the Prohibited List in 2018 under section S2.3, covering peptide hormones, growth factors, and related substances.^[7] The prohibition applies both in-competition and out-of-competition, so the timing of use does not create a safe window.

UK Anti-Doping (UKAD) applies the WADA Prohibited List to athletes in British sport. An athlete who tests positive for thymosin beta-4 metabolites faces the same sanctions as for any other S2 substance: a first violation carries a presumptive four-year ban, reduced only if the athlete can establish no significant fault. The fact that TB-500 is easily available online and sometimes described as a 'peptide supplement' is not a mitigating factor under the anti-doping rules.

WADA has funded research into TB-500 metabolism and detection methods, producing validated detection limits in urine and plasma samples. That research is publicly listed on the WADA scientific research database, which means testing authorities have practical methods to identify TB-500 use, not just a theoretical prohibition.

What TB-500 is not: clearing up common claims

TB-500 is sometimes described as being in a legal grey area, as a supplement, or as a peptide that is not subject to medicines law because it occurs naturally in the body. None of those framings hold up against the regulatory text.

It is not a dietary supplement. UK supplement law covers vitamins, minerals, and certain plant extracts. Peptides sold with claims about tissue repair and healing are assessed as medicinal products, not supplements, when they meet the definition in Regulation 2 of the Human Medicines Regulations.

It is not in a 'grey area' in the sense of being unaddressed by regulation. The MHRA framework is clear: no marketing authorisation, no approved supply. What is genuinely grey is enforcement consistency. The MHRA focuses its resources on sellers rather than individual buyers, and most parcels get through customs without incident. That gap between law and enforcement is not the same as the activity being lawful.

It is not a controlled drug under the Misuse of Drugs Act 1971. TB-500 is not scheduled as a Class A, B, or C substance. This means personal possession for non-supply purposes is not a Misuse of Drugs Act offence. The MHRA's enforcement authority under the Human Medicines Regulations operates separately from the drug-scheduling framework.

What changed in the past 12 months

The regulatory status of TB-500 in the UK has not changed in the past 12 months. No marketing authorisation was submitted or granted. No MHRA safety alert specific to TB-500 was issued in the period to July 2026.^[1] The product remains unauthorised.

The context around TB-500 has shifted somewhat in adjacent jurisdictions. In the US, the FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 at its July 2026 meeting as part of a broader assessment of seven peptides under the 503A bulks list. The outcome of that review affects whether US compounding pharmacies can continue to compound the product, not whether it is approved. The UK has no equivalent compounding framework for TB-500, and the US PCAC outcome has no direct legal effect in Great Britain.

A 2026 review in Sports Medicine covering approved and unapproved peptide therapies for musculoskeletal injuries confirmed that thymosin beta-4 and TB-500 remain without a regulatory approval pathway in any Western jurisdiction.^[8] That review is a useful reference point for clinicians and patients looking for an up-to-date summary of where human evidence actually stands.

Where this leaves UK readers

TB-500 is not a medicine you can obtain through a UK pharmacy, a GP, or any NHS route. There is no approved product to prescribe, and the specials pathway is not realistic for most people given the absence of human trial evidence. If you are considering TB-500 for any health purpose, the conversation belongs with a clinician who can review your specific situation and the actual state of the evidence.

For the cross-country picture on TB-500's regulatory status, see the TB-500 peptide page and the UK regulation hub.